Fiera Capital Corp acquired a new stake in shares of NuVasive, Inc. (NASDAQ:NUVA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 78,708 shares of the medical device company’s stock, valued at approximately $6,055,000. Fiera Capital Corp owned 0.15% of NuVasive at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Teachers Advisors LLC grew its position in shares of NuVasive by 205.8% during the 1st quarter. Teachers Advisors LLC now owns 249,546 shares of the medical device company’s stock valued at $18,636,000 after acquiring an additional 167,950 shares during the period. Bank of Montreal Can grew its position in shares of NuVasive by 23.6% during the 2nd quarter. Bank of Montreal Can now owns 5,680 shares of the medical device company’s stock valued at $437,000 after acquiring an additional 1,086 shares during the period. Geneva Advisors LLC grew its position in shares of NuVasive by 3.3% during the 2nd quarter. Geneva Advisors LLC now owns 17,369 shares of the medical device company’s stock valued at $1,336,000 after acquiring an additional 555 shares during the period. Neuberger Berman Group LLC grew its position in shares of NuVasive by 8.9% during the 2nd quarter. Neuberger Berman Group LLC now owns 439,121 shares of the medical device company’s stock valued at $33,777,000 after acquiring an additional 35,866 shares during the period. Finally, BNP Paribas Arbitrage SA grew its position in shares of NuVasive by 120.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 26,446 shares of the medical device company’s stock valued at $2,034,000 after acquiring an additional 14,427 shares during the period.

TRADEMARK VIOLATION NOTICE: “78,708 Shares in NuVasive, Inc. (NUVA) Purchased by Fiera Capital Corp” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/17/78708-shares-in-nuvasive-inc-nuva-purchased-by-fiera-capital-corp.html.

In other news, CEO Gregory T. Lucier purchased 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were bought at an average price of $61.52 per share, for a total transaction of $123,040.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Peter Michael Leddy purchased 7,850 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were purchased at an average price of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 14,850 shares of company stock worth $955,598. 1.20% of the stock is owned by company insiders.

NuVasive, Inc. (NASDAQ NUVA) opened at 58.48 on Friday. The company has a 50-day moving average of $63.17 and a 200 day moving average of $72.31. The company has a market cap of $2.97 billion, a P/E ratio of 92.09 and a beta of 1.08. NuVasive, Inc. has a one year low of $56.70 and a one year high of $81.68.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.40 earnings per share. Analysts anticipate that NuVasive, Inc. will post $2.00 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of NuVasive in a research report on Friday, July 28th. Royal Bank Of Canada upped their target price on shares of NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a report on Tuesday, June 6th. Barclays PLC reaffirmed a “buy” rating and issued a $80.00 target price on shares of NuVasive in a report on Wednesday, August 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $90.00 target price on shares of NuVasive in a report on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $79.00 target price on shares of NuVasive in a report on Sunday, July 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $80.42.

NuVasive Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.